No major moves in the US stock market this Wednesday morning, as investors digest retail earnings reports and are keeping an eye on oil prices. Analysts are expecting the market to be calm over the next few weeks, except for any shocks, as the stocks continue to trade in a tight range.
In this article we’ll explore a bunch of earnings reports issued on Tuesday after the closing bell. Let’s see how Ambac Financial Group, Inc. (NASDAQ:AMBC), Yelp Inc (NYSE:YELP), Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE), Coherus Biosciences Inc (NASDAQ:CHRS) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) have fared in the second quarter.
While there are many metrics that investors can assess in the investment process, hedge fund sentiment is something that is often overlooked. However, hedge funds and other institutional investors allocate significant resources while making their bets and their long-term focus makes them the perfect investors to emulate. This is supported by our research, which determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor beat the S&P 500 by around 95 basis points per month (see more details here).
Revenue Miss Hurts Ambac Financial Group
Ambac Financial Group, Inc. (NASDAQ:AMBC) shares are down by 4%, despite second quarter earnings that exceeded expectations. The company posted adjusted earnings of $2.54 per share, topping analysts’ forecasts of $1.05 per share, and $106.7 million in revenue, lower than the $119 million investors were expecting. So far this year, the stock has been a solid performer, having advanced 36% to yesterday’s closing price of $19.20 per share. At the end of the first quarter, approximately 22% of Ambac Financial Group, Inc. (NASDAQ:AMBC) common stock was held by 17 of the funds followed by Insider Monkey, up from 16 funds a quarter earlier.
Surprise Profit at Yelp
Shares of Yelp Inc (NYSE:YELP) has surged by 14% higher this morning after the company swung to a surprise profit and raised its full-year guidance. The company’s turnaround efforts are starting to pay off, as strong local ad sales have fueled an unexpected quarterly profit. Revenues rose by 30% year-over-year to $173.4 million, topping the estimates of $169.8 million, and Yelp reported a profit on $0.01 per share, up from a loss of $0.02 per share reported a year ago. The company increased its third-quarter revenue forecast to $180 million to $184 million, ahead of analysts’ consensus estimate of $179.6 million, and also sees full-year revenue ranging between $700 million and $708 million. The hedge fund sentiment towards Yelp Inc (NYSE:YELP) took a nosedive during the first quarter, as the number of long positions dropped to 33 at the end of March from 42 registered at the end of December.
Turn the page to read about the earnings posted by the remaining three companies in the list.
Coca Cola Bottling’s Business Running Smooth
A glimmer of hope for shareholders of Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE), as the stock has advanced by nearly 10%. The company posted a profit of $15.7 million, or $2.01 per share when adjusted for non-recurring costs. Revenues came in at $840.4 million, up by 27% year-over-year. Not to be confused with The Coca-Cola Co (NYSE:KO), Coca-Cola Bottling is only responsible for the packaging of beverages and the subsequent distribution and marketing. The company has a market cap of $1.32 billion and pays an annual dividend of $1.00 per share, providing investors with a 0.71% yield. Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) is not a very popular stock among the funds we follow, with only six of them having reported a stake at the end of March.
Coherus Biosciences Posts A Loss
Spurred by the earnings report released on Tuesday after the closing bell, Coherus Biosciences Inc (NASDAQ:CHRS) opened 2% higher this morning, but quickly took a nosedive and plunged by 8% and currently is trading at over 4% in the red. The developer of biosimilar therapeutics reported a loss of $70 million for the second quarter, or $1.72 per share, missing the estimates by $0.40. Revenue came in at $14.1 million, up 105% year-over-year. So far this year, the stock has been in an uptrend, gaining roughly 32% through yesterday’s closing price of $29.70 per share. At the end of the first quarter, Coherus Biosciences Inc (NASDAQ:CHRS) could be found in the portfolios of 11 of the funds we track, down from 12 recorded three months earlier.
Another Biotech, Another Loss
Investors are pushing Halozyme Therapeutics, Inc. (NASDAQ:HALO) lower as well, guided by the company’s second quarter report. Halozyme posted a loss of $26.9 million, which translates into $0.21 per share, ahead of analysts’ forecasts of a loss of $0.26 per share. Revenue came in at $33.3 million, down by 23% year-over-year. The company also said it expects full-year revenue to fluctuate between $140 million and $150 million. Halozyme is a biotechnology company that develops and commercializes human enzymes, which are used to improve the delivery of injected drugs and fluids. So far this year, the stock has been deep in the red zone, currently down by 40%. According to our data at the end of the first quarter, 16.5% of Halozyme Therapeutics, Inc. (NASDAQ:HALO) common stock was held by 17 of the funds we track, up from 16 funds that reported stakes as of the end of 2015.